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Despite recent advances in vascular cell biology,
patency of small-diameter vascular grafts remains
poor, and there are no acceptable prosthetic grafts
for vessels 4 mm or less in diameter.1 The use of
endothelial cells (ECs) to line a synthetic graft has
shown promise in animal models in the improve-
ment of patency rates, and genetic modification of
these cells could be of further benefit.2
Effective application of these techniques in
patients, however, will require an easily accessible
source of ECs. One possible source of EC is cultures
grown from ECs or their progenitor cells circulating
in peripheral blood, which would eliminate the need
for surgical removal of veins for cell harvest. We have
developed methods to isolate these cells from
human umbilical cord and adult peripheral blood
that provide culture conditions to promote the
development of ECs for use in seeding prosthetic
grafts and for gene therapy.3,4
METHODS
Isolation of umbilical cord blood ECs.
Umbilical cord blood (15-30 mL/sample) was
obtained from 63 patients shortly after delivery and
was placed into heparinized tubes. The blood was
collected with minimal handling of the vessel. The
sample was diluted 1:1 with phosphate-buffered
saline solution, added to a Ficoll gradient, and cen-
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Purpose: We have developed techniques to isolate endothelial cell (EC) progenitors from
human peripheral and umbilical cord blood.
Methods: Human adult peripheral and umbilical cord blood monocytes were isolated by
centrifugation, and progenitor cells were separated with the use of magnetic polystyrene
beads that were coated with a monoclonal antibody specific for the CD34 cell–mem-
brane antigen. Cells were propagated in selective media, and developing cultures were
immunostained for CD31, CD34, factor VIII, and vascular endothelial growth factor
cell receptors. ECs that developed were transfected with a gene for prourokinase and
used to line ePTFE grafts, which were evaluated in vitro in a pulsatile flow system. 
Results: Umbilical cord monocyte cultures demonstrated colonies that resembled ECs at
approximately 2 weeks, with growth being best supported by EC growth media plus
20% calf serum with iron. Immunostaining of colonies was positive for CD31 and fac-
tor VIII. After 18 days in culture, CD34+ cells from adult peripheral blood were noted,
which had the typical cobblestone appearance of ECs and immunostained positively for
CD31 and factor VIII–related antigens. Cultures of umbilical cord–derived cells and
adult peripheral blood–derived cells developed complex line formations within 1 week
in culture that stained positively for vascular endothelial growth factor receptor-2.
Urokinase-transfected ECs were shown to overexpress urokinase. Prosthetic grafts lined
with transfected cells showed 87.33% ± 4.97% cell adherence after 2 hours in a pulsatile
flow system at clinically relevant shear stress.
Conclusion: We conclude that endothelial progenitor cells can be isolated from human
adult peripheral and umbilical cord blood and developed into EC cultures as a source of
cells for vascular graft seeding and gene therapy. (J Vasc Surg 2000;31:181-9.)
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trifuged at 1400g for 10 minutes. The buffy layer was
removed and diluted 1:1 with phosphate-buffered
saline solution and centrifuged at 400g for 7 minutes.
The pellet was resuspended in Modified Dulbecco’s
Basic Salt Solution and centrifuged again at 400g for
7 minutes. This procedure was then repeated two
more times. The cell pellet was resuspended in media
and placed in T-25 flasks (Corning, Cambridge,
Mass), coated with a matrix, and incubated at 37°C,
97% humidity, and 4.5% carbon dioxide. Twenty-one
of the 63 samples were divided and cultured under
more than one matrix/media condition for a total of
88 experimental trials. Three different culture matri-
ces were used: gelatin (2 mg/mL), fibronectin (0.1
mg/mL), and fibronectin/gelatin (0.05 mg/mL, 1
mg/mL). Cell counts were not performed on
mononuclear preparations isolated from umbilical
cord blood. In each case, the entire mononuclear
preparation was divided between several flasks at
approximately equal cell density. 
Five different media were initially used for the
cord blood monocyte cultures: Dulbecco’s modified
eagle media (DMEM) plus 20% calf serum with
iron; Rosewell Park Memorial Institute (RPMI) plus
10% calf serum with iron; RPMI plus 10% calf serum
with iron and basic fibroblast growth factor (bFGF);
EC growth media plus 20% calf serum with iron4;
and EC growth media without serum plus bFGF.
For all cultures, one half of the media was changed
three times per week. 
Isolation of human peripheral blood EC. The
experimental protocol was approved by the William
Beaumont Hospital Human Investigation Committee,
and all subjects gave informed consent before blood
was drawn. Approximately 50 mL of human peripher-
al blood from 5 healthy adult (1 female and 4 male)
volunteer donors (aged 20 to 52 years) was drawn
from the cephalic vein at the antecubital fossa into
tubes containing 100 USP sodium heparin. The initial
portion of the drawn blood was discarded to eliminate
possible contamination of the sample with cells
released from the vessel wall during the needle stick.
After being mixed with an equal amount of isolation
buffer, mononuclear cells were isolated with the use of
a Ficoll gradient and centrifugation at 800g for 20
minutes. The buffy coat was harvested from the gradi-
ent. Uniform, magnetic, polystyrene beads (Dynal,
Lake Success, NY), which were coated with a mono-
clonal antibody specific for human CD34, were used
according to manufacturer protocol to separate
endothelial progenitor cells and any CD34+ ECs. Cells
were incubated with beads at ratios that ranged from
0.5 beads per cell to 5 beads per cell; most experiments
were performed at 1 bead per cell. Beads were sepa-
rated from the suspension with a Magnetic Particle
Concentrator (Dynal). Selected CD34+ cells were
detached from the magnetic beads by use of an anti-
body against the Fab portion of the monoclonal anti-
body to CD34. CD34– cells were isolated from the
remaining suspension by centrifugation. Each cell pop-
ulation was then resuspended in EC growth media
plus 20% calf serum with iron. After the harvest, cells
were placed for culture into T25 flasks coated with a
matrix of 2 mg/mL gelatin or 0.1 mg/mL fibro-
nectin; some cells were placed in matrix-coated cham-
ber slides or 35-mm dishes for immunostaining.
Cultures were incubated at 37°C, 97% humidity, and
4.5% carbon dioxide. One half of the culture media
was changed three times per week. Typically, cells were
passaged when they reached 30% to 50% confluence.
All experimental data reported is for cells from passage
number 3 or below. Two human peripheral blood sam-
ples were subjected only to the gradient centrifugation
method used in isolating umbilical cord monocytes
without the use of polystyrene beads for CD34+ selec-
tion and then placed in culture (as mentioned earlier).
Immunostaining. Cell line formations and
colonies that appeared in umbilical cord monocyte
cultures were identified by immunostaining for 
vascular endothelial growth factor receptor-2
(VEGF-R; Santa Cruz Biotechnology, Santa Cruz, 
Calif), factor VIII vonWillebrand–related antigen
(Shandon Lipshaw, Pittsburgh, Pa), and CD31
(Dako Corporation, Carpinteria, Calif) and by the
incorporation of 1,1´dioctadecyl-3,3,3´,3´-tetra-
methylindo-carbocyanine perchlorate acetylated low
density lipoprotein (DiI-Ac-LDL). Once cell
colonies were identified in peripheral blood cultures
from CD34+ cells, immunostaining was performed
for factor VIII, VEGF-R, CD31, and CD34
(Novocastra Laboratories, Vector Laboratories,
Burlingame, Calif). A double-staining technique was
used for simultaneous staining of factor VIII and
VEGF-R (Zymed Laboratories, San Francisco,
Calif). Both umbilical cord and peripheral blood cul-
tures were periodically checked for contamination
with smooth muscle cells or fibroblasts, and cells
with suspect morphologic features were removed
with a rubber policeman. Cultures of these cells
were immunostained with a monoclonal anti-human
smooth muscle cell actin antibody (Shandon
Lipshaw) to assess possible contamination.
Transduction of EC with preprourokinase
and lining of prosthetic grafts. EC were trans-
fected with a retroviral vector of the LN series that
contained the gene for human prourokinase and
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selected in medium containing G418, as previously
described.3,4 Urokinase production of transduced
cells relative to nontransduced control ECs reserved
for this purpose was quantified immunochemically
with a commercial enzyme-linked immunosorbent
assay kit (American Diagnostica, Greenwich,
Conn).3,4 The supernatants from matched cultures
of transduced cells and nontransduced control cells
were assayed for urokinase production for the 10 to
12 days immediately after transduction. 
Four-millimeter expanded polytetrafluoroethyl-
ene (ePTFE) grafts (W.L. Gore and Associates,
Flagstaff, Ariz) were lined with transduced ECs with
the technique originally described by Kesler et al5
and subsequently modified in our laboratory to
enhance cell attachment.3,4,6 Before graft seeding
was performed, recovery of cells was allowed for 7
days after exposure to G418 to increase cell adher-
ence.3 EC-lined grafts were incubated 4 days in cul-
ture medium after seeding before they were tested in
the pulsatile flow apparatus; this incubation period
also improved adherence.3
Pulsatile flow system. Urokinase-transduced
peripheral blood–derived ECs were tested for physi-
cal stability of the graft lining under simulated arte-
rial blood flow conditions. Before the graft was con-
nected to the pulsatile flow apparatus, a section was
removed for preflow analysis. A 6-cm segment of
lined graft was tested in the pulsatile flow system
(Harvard Apparatus, South Natick, Mass) pump by
the insertion of the linear adaptors into the graft and
the binding of the graft to the adaptor with two
suture knots and two smooth bulldog clamps at each
juncture. Pump settings were 30% output phase
ratio (duty cycle), 60 strokes/min, and 10
mL/stroke, which yielded a calculated shear stress of
9.45 dynes/cm2. The entire flow system was placed
in an incubator at 37°C and run for 2 hours. At the
end of the flow simulation, the grafts were discon-
nected and immersed in 10% neutral buffered for-
malin for fixation. The preflow and postflow graft
sections were stained with hematoxylin and analyzed
for cell adherence.
Image analysis of graft. Surface characteristics
of each graft were evaluated preflow and postflow by
computerized image analysis. A high-resolution video
image of the hematoxylin-stained graft surface was
digitized and stored in memory (Optimas Software,
Media Cybernetics, Silver Springs, Md). The number
of adherent cells per graft surface area was calculated
with a blinded procedure with the operator unaware
of the graft history. An average of five repeat, nonse-
quential analyses of each graft segment were per-
formed. Validation studies of this technique have
shown that repeat measures done in a blinded fashion
on the same sample typically show a variance of less
than 5%. 
Scanning electron microscopy. Samples for
scanning electron microscopy were taken from pre-
flow and postflow grafts at several points throughout
the interior of the graft. Samples were processed in
the standard fashion and examined for cell distribu-
tion and cell surface characteristics.
RESULTS 
Growth of umbilical cord blood-derived ECs.
The effect of matrix on EC development was
examined by dividing 19 umbilical cord monocyte
samples and culturing each on both gelatin and
fibronectin matrices. EC development and line for-
mation were independent of matrix. In the 19 sam-
ples, 10 developed EC colonies: four colonies on the
fibronectin matrix and six colonies on the gelatin
matrix (P > .5). In another experiment in which two
umbilical cord samples were each cultured on
gelatin, fibronectin, and 1:1 gelatin:fibronectin mix
as matrix, lines that resembled vasculogenesis
formed in all six cultures within the first 7 days; only
two of these cultures developed EC colonies (gelatin
and 1:1 fibronectin:gelatin matrices). Two mil-
ligrams per milliliter of gelatin was used as the matrix
for the remaining 42 umbilical cord samples.
The growth of umbilical cord monocyte cultures
in various media formulations is summarized in Table
I. Cultures grown in EC growth media plus 20% calf
serum with iron developed colonies that resembled
the typical cobblestone morphologic features of ECs
in 17 of 51 (33%) samples. In 1 of 22 (4%) samples
that used DMEM plus 20% calf serum with iron,
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Table I. Umbilical cord–blood culture growth in
various media formulations
Media Endothelial cells Line formations
DMEM + 20% 1/22 (4%) 10/22 (46%)
serum + Fe
EC Growth 17/51 (33%) 9/51 (18%)
Media + 20% 
serum + Fe
EC Media 0/2 0/2
(serum free) 
+ bFGF
RPMI + 10% 0/10 1/10 (10%)
serum + Fe 
+ bFGF
RPMI + 10% 0/3 0/3
serum + Fe
colonies resembling ECs developed. Lines that resem-
bled incipient vasculogenesis were seen most fre-
quently in cultures with DMEM plus 20% calf serum
with iron. No growth patterns were seen in cultures
supported by the other three media solutions. 
Initially in umbilical cord monocyte cultures, most
of the cells were small and round with many random
giant multinucleated cells throughout. Over time, the
giant cells decreased in number and became less
nucleated, and the smaller cells increased in predomi-
nance. Lines resembling the first stages of vasculogen-
esis appeared as early as 4 days in culture (more com-
monly, 1-2 weeks). There was great variability in line
appearance, from multiple thin strands to thicker
tubular-appearing structures. Early lines appeared as a
single row of aligned cells, which in some cases fur-
ther elongated or developed into thickened struc-
tures. Complex lines consisted of a double row of
elongated cells in contact with each other on the
periphery, surrounding a core of almost cuboidal cells
up to several cells wide. Line formations usually con-
tinued to increase in complexity for up to 3 weeks
then gradually became disorganized and disappeared.
EC colonies were first visualized at approximately 2
weeks and subsequently increased in size over time.
The appearance of line formations did not necessarily
predict future EC development, and EC colonies did
grow without previous line formations. 
Immunostaining for VEGF-R was positive at 1
and 2 weeks for large cells and those involved in line
formations. At 3 weeks, VEGF-R staining was posi-
tive for cells in EC colonies and line formations.
Immunostaining for factor VIII was negative at 1
week for all cells but became positive as soon as small
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Fig 1. Human umbilical cord monocyte cultures: A, early EC colonies (3-15 cells, arrows)
with positive staining for factor VIII (red), VEGF-R (blue-black) staining positively on some
surrounding cells (original magnification, ×100); B, later EC colony with positive staining for
factor VIII (original magnification, ×40); C, EC staining for CD31 (red; arrows) visible on
periphery of cells (original magnification, ×200); and D, EC colony identified by uptake of
DiI-Ac-LDL (orange fluorescent; original magnification, ×100).
A B
C D
colonies of ECs were identified (Fig 1, A). In some
early EC colonies, mixed staining of VEGF-R and
factor VIII was observed. Staining for factor VIII
increased as the EC colonies grew and remained
positive as long as the EC colonies remained in cul-
ture up to a maximum of 14 weeks (Fig 1, B).
Immunostaining for CD31 showed good edge stain-
ing of 60% of ECs in defined colonies and continued
to be positive up to the 9 weeks these cells were kept
in culture (Fig 1, C). Fluorescence of internalized
DiI-Ac-LDL was positive for colonies with EC mor-
phologic features in culture at 10 weeks (Fig 1, D).
Human umbilical cord mononuclear cell cultures
showed positive staining with anti-human smooth
muscle cell actin antibody of an occasional cell in
only 1 of 10 cultures from individual cord blood
samples tested.
Growth of adult peripheral blood-derived
ECs. A mean of 1.44 ± 0.18 × 105 cells were iso-
lated in the mononuclear preparation per milliliter of
peripheral blood by Ficoll gradient centrifugation.
Cultures of adult human peripheral blood that were
subjected only to gradient centrifugation to isolate
mononuclear cells developed line formations that
resembled the initial stages of vasculogenesis in two
cultures (Fig 2). No colony growth resembling ECs
was identified in these cultures.
Cultures from CD34 magnetic bead–selected
adult human peripheral blood cells demonstrated
growth of ECs with typical cobblestone morpholog-
ic features after 18 days (Fig 3, A). Line formations
that resembled vasculogenesis (as described earlier
for umbilical cord blood cultures) were identified in
some cultures from cells not adhering to CD34 mag-
netic beads (CD34– cells). No EC colonies were seen
in cultures from CD34– cells. Immunostaining for
CD31 on cultures from CD34+ cells with colonies of
ECs was positive when tested at 5 and 8 weeks, with
the same pattern of edge staining seen in umbilical
cord blood cultures. Immunostaining for CD34 after
8 weeks in the cultures from initially CD34+ cells
demonstrated 20% staining of cells within EC
colonies (Fig 3, B). Factor VIII immunostaining was
also positive in ECs cultured from CD34+ cells when
tested at 5 and 8 weeks (Fig 3, C). Two human
peripheral blood cultures showed negative immuno-
staining results when tested with anti-human smooth
muscle cell actin.
Urokinase production by transduced ECs and
pulsatile flow studies. By 5 days in culture, uroki-
nase levels above background were detectable in
transduced cells (Fig 4). At 10 days after transduc-
tion, peripheral blood-derived ECs showed produc-
tion of urokinase at 0.084 ng/mL/hr/106 cells, and
umbilical cord–derived ECs at 10 days after trans-
duction showed production of urokinase at 0.154
ng/mL/hr/106 cells. Levels of urokinase in non-
transduced umbilical cord–derived cells were not
detectable above background; levels in nontrans-
duced peripheral blood–derived cells were 0.015
ng/mL/hr/106 cells (P > .05 compared with trans-
duced cells).
In two experiments that used transduced adult
peripheral blood–derived cells to line 4-mm ePTFE
grafts, the mean postflow retention of cells was
87.33% ± 4.97% of the number of preflow cells, a
change that was not significant by the Student t test
(P > .05). Similar levels of attachment were seen in
two experiments with transduced umbilical
cord–derived cells, in which a comparison of preflow
and postflow cell layers showed retention of 82.94%
± 25.95% of cells. Light microscope and scanning
electron microscope examination of the postflow
graft segments in these experiments showed mostly
even distribution of well-attached cells with typical
spindle-shaped or rounded EC appearance. Areas of
cell loss showed nondistinct cell boundaries or
roughened attachment. Occasional bare patches
found in both preflow and postflow grafts represent
lack of full coverage in seeding rather than detach-
ment because of shear stress.
DISCUSSION
The purpose of this study was to develop a
method for obtaining EC precursors from human
blood to be used as a source of ECs for seeding pros-
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Fig 2. Human adult peripheral monocyte culture (gradient
separation only) demonstrates line formation (arrows) that
resembles vasculogenesis. (Unstained; original magnifica-
tion, ×100.)
thetic vascular grafts and for use in gene therapy.
Human prosthetic vascular grafts infrequently form
an endothelial layer on the lumenal side unlike
canine, bovine, and porcine animal models,
although Berger et al7 showed in 1972 that humans
have ingrowth of approximately 2 to 4 mm from
both the proximal and distal anastomoses, never
exceeding 10 mm; Shi et al8 identified endothelial-
ized patches in some human long-term Dacron
grafts that had been fixed immediately after death.
To answer the question as to whether animals
endothelialize grafts by ingrowth or whether ECs or
EC progenitor cells are circulating in peripheral
blood, Stump et al9 provided evidence for the pres-
ence of ECs in the peripheral blood by observing
canine ECs adherent on an intravascular Dacron
hub. ECs were shown to exist in peripheral blood by
Scott et al,10 possibly as progenitor cells. Fallout
endothelialization was shown to occur in the middle
section of the lumen of canine vascular grafts in
small patches with experimental Dacron-ePTFE-
rubber vascular grafts that prevented EC migration
through the wall of the vascular graft; anastomotic
pannus ingrowth did not extend beyond 13 mm in
any specimen in this study.11 More recently, with the
same type of graft, the middle section ECs were
shown to be derived from the bone marrow, sugges-
tive of EC progenitor cell fallout endothelialization
from the blood.12 These studies suggest that ECs
and/or their progenitor cells exist in peripheral
blood of both humans and animals.
Other investigators have studied hematopoietic
progenitor cells from adult peripheral blood and
from umbilical cord blood. Blood stem cell pools
and bone marrow are in dynamic equilibrium with
each other, thus allowing migration of cells between
extravascular marrow sites and the circulation.13
Cord blood contains 20 times the number of clono-
genic progenitor cells than adult peripheral blood.14
Recently, methods have been developed for ex vivo
hematopoietic expansion15 and isolation and purifi-
cation techniques for desired cell populations.16,17
Much of this work relates to the isolation and in
vitro development of ECs.18
Studies in the field of vasculogenesis show that
the hemangioblast is a common precursor for both
hematopoietic cells and ECs; the hemangioblast dif-
ferentiates into (1) hematopoietic stem cells and (2)
EC precursor cells.19,20 CD34 is the common sur-
face marker for cells of the hematopoietic lineage
but is also found on capillary ECs, less on larger ves-
sels,21 and in a posttranslationally processed form in
the high endothelium of the postcapillary venules of
lymph nodes.22 CD34 expression is downregulated
in mature ECs in culture.21 EC surface receptors
that appear early in development are VEGF recep-
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Fig 3. Human peripheral blood cultures (magnetic bead
separation): A, CD34+ cell fraction shows colony with typi-
cal EC morphologic features (unstained; original magnifica-
tion, ×100); B, CD34 staining of initially CD34+ ECs, note
random staining pattern (brown, arrows; original magnifica-
tion, ×200); and C, factor VIII staining (red, granular) of




tor-1 and -2, vascular endothelial cadherin (also
known as cadherin-5), platelet endothelial cell
adhesion molecule-1 (CD31), tie-1, tie-2, and
CD34.22 There are two tyrosine kinase receptors
for VEGF expressed on the surface of various ECs,
flk-1 and flt-1. In normal development, VEGF
receptors appear to be expressed during vasculogen-
esis and early vascular differentiation.23 Consistent
with this, we find VEGF-R staining in line forma-
tions and in early EC colonies. The development of
lines that stain positively for VEGF-R, well before
EC can be identified in culture, suggest that these
lines are being formed by progenitor ECs. In early
EC colonies, immunostaining for CD31 showed
good edge staining that was consistent with its con-
centration at cell borders where it mediates cell-cell
adhesion and transduces intracellular signals.24,25
Cells in our cultures develop increasing levels of fac-
tor VIII over time; it has been reported that mature
ECs in culture may lose factor VIII expression as
cells approach senescence.26,27 The progression of
cell types and surface markers seen in our cultures is
strongly suggestive of the development of EC 
precursors.
In these studies, inclusion of mature ECs
released from vessel walls cannot be entirely ruled
out; however, steps were taken to minimize the
handling of the vessels, and the initial portion of
each peripheral blood draw was discarded specifical-
ly to exclude this possibility. Previous experience in
our laboratory with cultures of mature vascular
endothelial cells has shown that ECs from vessel
walls are less fragile and show stronger attachment
to the matrix than progenitor cells. Especially in
umbilical cord samples, mature ECs plate down
immediately, grow very rapidly, and never show the
migration of cells into lines resembling the first
stages of vasculogenesis. ECs in this study developed
over 18 days in culture and were not identifiable as
ECs until that time, further suggesting that they
were not present as mature ECs in the blood col-
lected, but developed from precursor stem cells.
Isolation of ECs and progenitors from human
cord blood led us to the study of adult human
peripheral blood. Gradient centrifugation alone with
culture of the resulting monocyte fraction produced
lines of cells that appeared more developed than
those in the CD34– fraction, probably because of
growth factors or matrix components produced by
cells that are removed during magnetic bead separa-
tion. These lines are quite similar to incipient vascu-
logenesis as reported by Risau and Flamme.28 Several
growth factors have been identified with vasculogen-
esis, including VEGF, bFGF, heparin, and the unde-
fined endothelial cell growth supplement and tumor-
conditioned culture supernatant.28
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Fig 4. Overexpression of urokinase by genetically modi-
fied peripheral blood–derived endothelial cells (A) and
umbilical cord–derived endothelial cells (B). Urokinase
production quantified by enzyme-linked immunosorbent
assay of culture supernatants over 10 and 12 days after
transduction with a retroviral vector containing the gene
for human prourokinase. Control medium is culture
supernatants from matched nontransduced cells.
A
B
Similar work to ours has been recently reported by
Asahara et al29 who described separation of EC prog-
enitors only from adult human peripheral blood by
the magnetic bead method. They found fully differ-
entiated ECs after 7 days in culture, compared with
18 days for our adult peripheral blood cultures. Their
results also differ from ours in that they found lines of
cells, somewhat dissimilar to ours, in the CD34+ frac-
tion. We found such line formations in the CD34–
fraction or the cultured unfractionated monocyte
preparation, which shows the most complex lines of
cells. The lack of correlation between line formation
and EC colony development in CD34+ and CD34–
fractions may indicate that different populations of
progenitor cells are involved or that the growth fac-
tors required for differentiation and/or vasculogene-
sis are not produced in the CD34+ fractionated pop-
ulation. Additionally, Lindner et al30 have suggested
that activated mononuclear cells may secrete sub-
stances inhibitory or toxic to EC colony development,
but which do not inhibit the incipient vasculogenesis
seen in our cultures. Further refinements in growth
conditions presented to unfractionated mononuclear
cell preparations or the CD34– fraction (such as the
addition of growth factors, use of conditioned medi-
um, alterations in feeding schedule, mechanical
removal of cells or the specific isolation of progenitor
cells) may enhance the development of any EC pre-
cursors found in these populations. The use of a thick-
er matrix may encourage the development of true
tubular structures from the line formations we have
observed.
In previous studies, we transduced canine EC
derived from surgically harvested jugular vein with
the gene for prourokinase and used these cells to line
prosthetic ePTFE grafts.3 In this study we have
shown similar transduction of human umbilical cord
and peripheral blood–derived cells. With the use of
the culture techniques described, these cells remain
more adherent under clinically relevant pulsatile
flow conditions in vitro than have been reported in
other studies for transduced cells producing tissue
plasminogen activator.31 ECs cultured by these
methods show potential for prosthetic graft applica-
tions, although in vivo testing in humans remains to
be done.
In conclusion, these studies indicate that human
peripheral blood may provide a reliable source of
endothelial cells for graft seeding and gene therapy,
and this technique combined with methods of tissue
engineering has the potential to produce a small
diameter vessel. These are areas that warrant further
investigation.
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